Theme: Innovative Ideas and Approaches for Striving the Future of Diabetes.
The GSC invites all the participants across the globe to attend the Global Conference and Expo on Diabetes which will be held in March 11th-12th, 2019 Dubai UAE. which will provide an international platform for discussion of present and future challenging and emerging issues in Diabetes. Diabetes 2018 will also provide the excellent opportunity to meet Physicians, Researchers, Clinicians, Experts, Directors, Professors, Associate Professors, Dietitians, Certified diabetes educators, other health care professionals and who manage diabetes related complications.
- Diabetic Types
- Diabetes symptoms (Gender specific and Common)
- Risk Factors For Diabetes
- Pathophysiology of Diabetes
- Oral and dental Complications of diabetes Mellitus
- Micro and Macrovascular Complications of Diabetes
- Diabetic Heart Diseases (DHD)/ diabetes-cardiovascular-complications
- Diabetic Nursing
- Oral anti-diabetic medications
- New challenges and therapies to diabetes
- Pharmacognostic/Herbal Approach to diabetes
- Chemotherapeutic Management of Diabetes
- Stem Cell therapy-Novel Approach to diabetes
- Genetics of diabetes
- Transplantations involved in diabetes
- Metabolic Syndrome / Syndrome X
- Clinical Diabetes and Diagnostic Approaches
The GSC invites all the participants across the globe to attend the Global Conference and expo on Diabetes, which will be held in March 11th-12th, 2019 Dubai UAE. which will provide an international platform for discussion of present and future challenging and emerging issues in Diabetes. Diabetes 2019 will also provide the excellent opportunity to meet Physicians, Researchers, Clinicians, Experts, Directors, Professors, Associate Professors, Dietitians, Certified diabetes educators, other health care professionals and who manage diabetes related complications.
Sessions and Tracks:
Track 1: Diabetic Types:
Diabetes is a number of diseases that involve problems with the hormone insulin, and also deficiency in the improper secretion of insulin cells, which is considered as an important factor to affect the people with that disease. Normally, the pancreas (an organ behind the stomach) releases insulin to help your body store and use the sugar and fat from the food you eat. If the diabetes occurs the major part of the pancreas region will be affected. The symptoms description for the diabetes is noted as Patients with high blood sugar will typically experience frequent urination; they will become increasingly thirsty and hungry. With diabetes mellitus, your body doesn’t make enough insulin; it can’t use the insulin which it produces, or a combination of both. High levels of blood glucose can cause damage the blood vessels in your kidneys, heart, eyes, or nervous system, lack of concentration and lack of consciousness. Diabetes is also occurring on the various types such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, gestational diabetes, juvenile diabetes and etc.
- Diabetic neuropathy
- Congenital diabetes
- Steroid diabetes
- Idiopathic diabetes
- Monogenic diabetes
- Pre diabetes
- Diabetes mellitus Type-1
- Diabetes mellitus Type-2
- Gestational diabetes (diabetes in pregnancy)
- Cystic fibrosis
Track 2: Diabetes symptoms (Gender specific and Common)
Men who have type 2 diabetes are twice as likely to have low testosterone (low-T) than men who do not have diabetes. Because of the low levels of the hormone testosterone, men with diabetes can have unhealthy symptoms that are not seen in women with diabetes.
Low testosterone can cause decreased sex drive, depression, lack of energy, and reduced muscle mass. It can also cause male-specific sexual problems and urological problems.
Erectile dysfunction (ED, impotence), or inability to get or maintain an erection, is a common symptom of diabetes in men. Diabetic men experience erectile dysfunction at earlier ages than men who do not have diabetes.
Another diabetes-related sexual dysfunction symptom in men is reduced amounts of ejaculation, or retrograde ejaculation. Retrograde ejaculation is a condition in which the semen goes into the bladder, rather than out of the body through the urethra. Diabetes and damage to the blood vessels causes nerve damage to the muscles that control the bladder and urethra, which results in this problem.
Gender specific –Male
- Erectile dysfunction (ED, impotence)
- Retrograde ejaculation
- Low testosterone (low-T)
- Decreased sex drive (decreased libido) and sexual dysfunction Common symptoms
- Polydipsia(increased thirst)-Early sign
- Frequent urination(Polyuria)
- Increased hunger (Polyphagia)
- Urine infections.
- Unexplained weight loss
- Fatigue (weak, tired feeling)
- Blurred vision and Headaches.
- Pain or numbness in your feet or legs
- Dry mouth and itchy skin
Track 3: Risk Factors For Diabetes:
About 90 percent of people with diabetes have Type 2 diabetes. It can come on slowly, usually over the age of 40. The signs may not be obvious, or there may be no signs at all, therefore it might be up to 10 years before you find out you having it.
Type 1 usually starts in childhood and your pancreas stops making insulin. Research shows this is a top reason for type 2 diabetes. Because of the rise in obesity among U.S. children, this type is affecting more teenagers. Type 2 diabetes often starts with cells that are resistant to insulin. That means your pancreas has to work extra hard to make enough insulin to meet your body’s needs. Diabetes happens more often in Hispanic/Latino Americans, African-Americans, Native Americans, Asian-Americans, Pacific Islanders, and Alaska natives. Women with polycystic ovary syndrome (PCOS) have a higher risk.
- Obesity or being overweight
- Impaired glucose tolerance
- Family history and Ethnic background
- Fat distribution: more fat around the middle
- High blood pressure and High cholesterol
- Sedentary lifestyle (lack of exercise and/or not physically active)
- Excessive Smoking and Alcohol intake
- Lack of sleep
- Diseases of the pancreas
Track 4: Pathophysiology of Diabetes:
Type 1 Diabetes Mellitus-In this condition the immune system attacks and destroys the insulin producing beta cells of the pancreas. There is beta cell deficiency leading to complete insulin deficiency. Thus is it termed an autoimmune disease where there are anti-insulin or anti-islet cell antibodies present in blood. These cause lymphocytic infiltration and destruction of the pancreas islets. The destruction may take time but the onset of the disease is rapid and may occur over a few days to weeks.
There may be other autoimmune conditions associated with type 1 diabetes including vitiligo and hypothyroidism. Type 1 diabetes always requires insulin therapy, and will not respond to insulin-stimulating oral drugs.
Type 2 Diabetes Mellitus-This condition is caused by a relative deficiency of insulin and not an absolute deficiency. This means that the body is unable to produce adequate insulin to meet the needs. There is Beta cell deficiency coupled with peripheral insulin resistance.
Peripheral insulin resistance means that although blood levels of insulin are high there is no hypoglycemia or low blood sugar. This may be due to changes in the insulin receptors that bring about the actions of the insulin.
Obesity is the main cause of insulin resistance. In most cases over time the patients need to take insulin when oral drugs fail to stimulate adequate insulin release.
- Insulin–Pancreatic anabolic Hormone
- Transport and metabolism of glucose
- Type 1 Diabetes Mellitus (destruction of the pancreatic beta cells) – genetic susceptibility
- Auto-immune reactions
- Type 2 Diabetes Mellitus
- Glycosuria(excretion of glucose into the urine)
- Hyperglycemic and hyperosmolar non ketotic syndrome
Track 5: Oral and dental Complications of diabetes Mellitus :
Several soft tissue abnormalities have been reported to be associated with diabetes mellitus in the oral cavity. These complications include periodontal diseases (periodontitis and gingivitis); salivary dysfunction leading to a reduction in salivary flow and changes in saliva composition, and taste dysfunction. Oral fungal and bacterial infections have also been reported in patients with diabetes. There are also reports of oral mucosa lesions in the form of stomatitis, geographic tongue, benign migratory glossitis, fissured tongue, traumatic ulcer, lichen planus, lichenoid reaction and angular chelitis. In addition, delayed mucosal wound healing, mucosal neuro-sensory disorders, dental carries and tooth loss has been reported in patients with diabetes. The prevalence and the chance of developing oral mucosal lesions were found to be higher in patients with diabetes compared to healthy controls.
Various inflammatory diseases and soft tissue pathologies in oral cavities are associated with diabetes mellitus; however, awareness of these complications is lacking worldwide. Periodontal diseases have been proposed as the sixth most prevalent complication of diabetes mellitus following the other diabetic complications. It has been reported as a more frequent oral complication of diabetes compared to other oral manifestations such as dry mouth and caries. Periodontitis is more frequent and severe in patients with diabetes with poor glycaemic control. Early identification and/or management of these oral manifestations may help in the early diagnosis of diabetes and in attaining better glycaemic control. Therefore, diabetic oral complications need to be identified and included in the ultimate care of diabetes in order to fight this chronic metabolic disease effectively.
- Periodontal diseases (periodontitis and gingivitis)
- Acute and Chronic Oral candidosis-Fungal Infections
- Denture induced stomatitis- Fungal Infections
- Angular chelitis and median rhomboid glossitis-Fungal Infections
- Bacterial Infections
- Dental Caries and Tooth Loss
Track 6: Micro and Macrovascular Complications of Diabetes:
The most common serious complications from diabetes are coronary artery disease (CAD) and stroke, kidney failure, blindness, and foot disease. All diabetes complications can require specialized medical treatment depending on their severity. Some of these conditions, such as CAD, may be adequately managed by your primary care doctor. If the disease progresses, you may need to see a specialist.
Symptoms of diabetes complications can develop when you have prediabetes, diabetes that has not been diagnosed early and even diabetes that has been treated.
High blood sugar causes changes in hormones and cells that can damage blood vessels or nerves, or both. Damaged blood vessels are more likely to build up plaque, increasing the risk of coronary artery disease, heart attack, and stroke. When large blood vessels are affected, complications are called macrovascular disease. Damage to small blood vessels can lead to loss of vision, kidney disease, and nerve problems throughout the body. When small blood vessels are affected, the condition is called microvascular disease.
Nerve damage (diabetic neuropathy) can decrease or completely block the movement of nerve impulses or messages through organs, legs, arms, and other parts of the body. Nerve damage can affect your internal organs and your ability to feel pain when you are injured.
- Diabetic cataracts(Ocular complications)
- Diabetic retinopathy(Ocular complications)
- Glaucoma(Ocular complications)
- Micro albuminuria and proteinuria (Nephropathic Complications)
- Progressive diabetic nephropathy(Nephropathic Complications)
- Peripheral neuropathy
- Autonomic neuropathy and Refractory diabetic diarrhea
- Chronic pyogenic infections (Skin and Mucous membrane complications)
- Eruptive xanthomas and Candidal infection (Skin and Mucous membrane complications)
- Necrobiosis lipoidica diabeticorum and Vulvovaginitis (Skin and Mucous membrane complications)
- Diabetic Ketoacidosis
Track 7: Diabetic Heart Diseases (DHD)/ diabetes-cardiovascular-complications:
People who have type 1 or type 2 diabetes can develop DHD. The higher a person’s blood sugar level is, the higher his or her risk of DHD.
Diabetes affects heart disease risk in three major ways.
First, diabetes alone is a very serious risk factor for heart disease, just like smoking, high blood pressure, and high blood cholesterol. In fact, people who have type 2 diabetes have the same risk of heart attack and dying from heart disease as people who already have had heart attacks.
Second, when combined with other risk factors, diabetes further raises the risk of heart disease. Although research is ongoing, it’s clear that diabetes and other conditions—such as overweight and obesity and metabolic syndrome—interact to cause harmful physical changes to the heart.
Third, diabetes raises the risk of earlier and more severe heart problems. Also, people who have DHD tend to have less success with some heart disease treatments, such as coronary artery bypass grafting and percutaneous coronary intervention, also known as coronary angioplasty.
Over time, high blood glucose from diabetes can damage your blood vessels and the nerves that control your heart and blood vessels. The longer you have diabetes, the higher the chances that you will develop heart disease.
People with diabetes tend to develop heart disease at a younger age than people without diabetes. In adults with diabetes, the most common causes of death are heart disease and stroke. Adults with diabetes are nearly twice as likely to die from heart disease or stroke as people without diabetes
- Coronary Heart Disease
- Angina and Arrhythmias
- Heart Failure
- Preeclampsia(Uncontrollable risk factor during pregnancy)
- Diabetic Cardiomyopathy
- Metabolic Syndrome and obesity (major factors of DHD)
- Percutaneous coronary intervention (coronary angioplasty)
- Coronary artery bypass grafting (CABG)
- Implantable cardioverter defibrillator (ICD)- cardiac resynchronization therapy
Track 8: Diabetic Nursing:
A diabetes nurse helps patients that have diabetes, a disease that prevents the body from producing or absorbing enough insulin. Since much of their job is spent relaying important information between patients, doctors, and family members, a diabetes nurse’s greatest asset is their ability to communicate. Many Diabetes Nurses become advocates for diabetes awareness and go on to become diabetes educators.
Diabetes is a disease of the endocrine system. Endocrine or endocrinology nurses may work with people who have diabetes, and go by the title diabetes nurse. As diabetes mellitus has become an increasingly common problem, there’s a growing need for diabetes nurse educators and disease management specialists able to provide patients with the information and treatment they need to effectively manage their diabetes.
A diabetes nurse can be a staff nurse who helps monitor and educate patients, or an advanced practice registered nurse (nurse practitioner or clinical nurse specialist) who can take on the added responsibilities of advanced diabetes management and education. These additional responsibilities often include adjusting the type and dosage of medication, providing nutritional therapy and exercise planning, and providing behavioral and psychosocial counseling. Advanced practice nurses who sub-specialize in endocrinology may serve as a diabetic’s primary healthcare provider.
- Monitoring and educating patients
- Behavioral and psychosocial counseling
- Nutritional therapy and exercise planning
- Diabetic’s primary healthcare provider
- Evaluating patients periodically
- Documenting the assessment and education plan,intervention
- Endocrine and Diabetes nurse educators
- Public and Community Health
- Quality Improvement and Research
Track 9: Oral anti-diabetic medications:
The first-generation sulfonylureas, once the only drugs available for treating type 2 diabetes, are not used much today. They have been replaced with second-generation agents that are more potent, have fewer drug interactions, and produce less significant side effects. Sulfonylureas stimulate pancreatic insulin secretion. The increased quantity of secreted insulin helps counteract the qualitative decrease in tissue sensitivity to insulin, allowing greater glucose entry into target cells and thereby lowering blood glucose levels. Sulfonylureas generally have a relatively long duration of action of 12 to 24 hours, depending on the drug, and are taken once or twice per day. Hypoglycemia is a major side effect of sulfonylureas. In patients taking these agents, food intake must be adequate to prevent glucose levels from falling too low.
Like the sulfonylureas, repaglinide stimulates pancreatic insulin secretion. However, its pharmacodynamic properties and mechanism of action are different from those of the sulfonylureas. Repaglinide is rapidly absorbed, reaches peak plasma levels in 30 to 60 minutes, and is then rapidly metabolized. The drug is taken with meals and lowers the peaks of postprandial plasma glucose common with type 2 diabetes to a much greater degree than the sulfonylureas are able to do.
Metformin is a biguanide agent that lowers plasma glucose mainly by preventing glycogenolysis in the liver. Metformin also improves insulin use, counteracting the insulin resistance seen with type 2 diabetes. Because metformin does not stimulate increased insulin secretion, hypoglycemia is much less common with this drug.
- Biguanides (Insulin sensitizers)
- Lyn Kinase Activators(Insulin sensitizers)
- Metformin-first-line medication
- Thiazolidinediones (Insulin sensitizers)
- Alpha-glucosidase inhibitors (Acarbose & Miglitol)
- Combined medication Therapy
Track 10: New challenges and therapies to diabetes:
Diabetes mellitus is a widespread disease prevalence and incidence of which increases worldwide. The introduction of insulin therapy represented a major breakthrough in type 1 diabetes; however, frequent hyper- and hypoglycemia seriously affects the quality of life of these patients. New therapeutic approaches, such as whole pancreas transplant or pancreatic islet transplant, stem cell, gene therapy and islets encapsulation are of major importance.
Regarding type 2 diabetes, therapy has been based on drugs that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), reduce hepatic glucose production (biguanides), delay digestion and absorption of intestinal carbohydrate (alpha-glucosidase inhibitors) or improve insulin action (thiazolidinediones) and new therapies focus on the newer therapeutically approaches such as incretin-based therapies, bariatric surgery, stem cells and other emerging therapies. Gene-based therapies are among the most promising emerging alternatives to conventional treatments. Some of these therapies rely on genetic modification of non-differentiated cells to express pancreatic endocrine developmental factors, promoting differentiation of non-endocrine cells into β-cells, enabling synthesis and secretion of insulin in a glucose-regulated manner.
- Incretin-based therapies
- Bariatric surgery
- Gene-based therapies
- Glycemic control
- Stem cell therapies
- Pancreatic Transplantations
- Conventional therapies
- Halozyme Therapeutics
- Gluconeogenesis inhibitors
Track 11: Pharmacognostic/Herbal Approach to diabetes:
Plants possessing antidiabetic properties may be suitable as adjunct to the existing therapies or as a prospective source of new hypoglycemic compounds. Since time immemorial, naturopathic therapies have been applied for a number of health ailments and continue to gain popularity in the present arena as well. Ancient literature revealed that diabetes was a known disease since Brahmic period and finds a mention in Ayurvedic literature, Sushruta samhita written in fourth and fifth centuries BC. Two forms of diabetes were described: one genetic in nature and the other due to dietary indiscretion. Herbal medicines are becoming immensely popular among the masses for being cost effective and with relatively few side effects. Although plant based medicines have been used traditionally in treating diseases throughout the world, the mechanism of most of the herbs is still to be defined and standardized. Many new bioactive drugs isolated from plants having hypoglycaemic effects demonstrate antidiabetic activity equal to and sometimes even more potent than known oral hypoglycaemic agents such as daonil, tolbutamide, and chlorpropamide. The chemical structures of a phytomolecule play a critical role in its antidiabetic activity. Several plant species being a major source of terpenoids, flavonoids, phenolics, coumarins, and other bioactive constituents have shown reduction in blood glucose levels.
- Gymnema Sylvestris
- Bilberry (Vaccinium myrtillus)
- Fenugreek Seed (Trigonella foenum graecum)
- Bitter Melon (Momordica charantia)
- Gingko biloba
- Goat’s Rue (Galega officinalis)
- Onion and Garlic
Track 12: Chemotherapeutic Management of Diabetes:
One of the most frequent complications of people with diabetes is foot disorders, specially foot ulcers or wounds. These wounds can easily become infected, and are known as diabetic foot infections (DFIs). If they are not treated, the infection can progress rapidly, involving deeper tissues and threatening survival of the limb. Sometimes these infections conclude with the affected limb needing to be amputated.
Most DFIs require treatment with systemic antibiotics, that is, antibiotics that are taken orally, or are inserted straight into the bloodstream (intravenously), and affect the whole body. The choice of the initial antibiotic treatment depends on several factors such as the severity of the infection, whether the patient has received another antibiotic treatment for it, or whether the infection has been caused by a micro-organism that is known to be resistant to usual antibiotics (e.g. methicillin-resistant Staphylococcus aureus – better known as MRSA). The objective of antibiotic therapy is to stop the infection and ensure it does not spread.
- Penicillins(bactericidal antibiotics)
- Cephalosporins (Cephalexin, Ceftriaxone, Cefoxitin)
- Carbapenems (broad-spectrum activity)
- Fluoroquinolones (Levofloxacin and Moxifloxacin)
- Anti-Infective Agents(Metronidazole,Clindamycin)
- Cyclic Lipopeptides (Daptomycin)
Track 13: Stem Cell therapy-Novel Approach to diabetes:
The incidence of diabetes and the associated debilitating complications are increasing at an alarming rate worldwide. Current therapies for type 1 diabetes focus primarily on administration of exogenous insulin to help restore glucose homeostasis. However, such treatment rarely prevents the long-term complications of this serious metabolic disorder, including neuropathy, nephropathy, retinopathy, and cardiovascular disease. Whole pancreas or islet transplantations have enjoyed limited success in some individuals, but these approaches are hampered by the shortage of suitable donors and the burden of lifelong immunosuppression. Stem cells hold great promise for pancreatic beta cell replacement therapy for diabetes. In type 1 diabetes, beta cells are mostly destroyed, and in type 2 diabetes beta cell numbers are reduced by 40 to 60percent . The proof-of-principle that cellular transplants of pancreatic islets, which contain insulin-secreting beta cells, can reverse the hyperglycemia of type 1 diabetes has been established, and there is now a need to find an adequate source of islet cells. Human embryonic stem cells can be directed to become fully developed beta cells and there is expectation that induced pluripotent stem (iPS) cells can be similarly directed. iPS cells can also be generated from patients with diabetes to allow studies of the genomics and pathogenesis of the disease. Some alternative approaches for replacing beta cells include finding ways to enhance the replication of existing beta cells, stimulating neogenesis (the formation of new islets in postnatal life), and reprogramming of pancreatic exocrine cells to insulin-producing cells. Stem-cell-based approaches could also be used for modulation of the immune system in type 1 diabetes, or to address the problems of obesity and insulin resistance in type 2 diabetes. Herein, we review recent advances in our understanding of diabetes and beta cell biology at the genomic level, and we discuss how stem-cell-based approaches might be used for replacing beta cells and for treating diabetes.
- Endocrine Progenitor Cells
- Beta-Cell Replication
- Directed Differentiation of Non endocrine Progenitors
- Generation of Islet Cells from Embryonic Stem Cells (ESCs)
- Induced Pluripotent Stem Cells for Islet Cell Generation
- Development of the Endocrine Pancreas
Track 14: Genetics of diabetes:
Several gene mutations have been linked to the development of type 2 diabetes. These gene mutations can interact with the environment and each other to further increase your risk. Type 2 diabetes is caused by both genetic and environmental factors.
Scientists have linked several gene mutations to a higher diabetes risk. Not everyone who carries a mutation will get diabetes. But many people with diabetes do have one or more of these mutations.
It can be difficult to separate genetic risk from environmental risk. The latter is often influenced by your family members. For example, parents with healthy eating habits are likely to pass them on to the next generation. On the other hand, genetics plays a big part in determining weight.
- Mitochondrial DNA mutations
- Defects in proinsulin conversion
- Insulin gene mutations
- Insulin receptor mutations
- Genetic-lifestyle interactions in the development and prevention of diabetes
- Recent advances in genetics of diabetes
- Diabetes in specific ethnic groups
Track 15: Transplantations involved in diabetes:
Type 1 diabetes results from the destruction of insulin-producing cells in the islets of the pancreas. Islet cell transplantation involves extracting islet cells from the pancreas of a deceased donor and implanting them in the liver of someone with Type 1. This minor procedure is usually done twice for each transplant patient, and can be performed with minimal risk using a needle under local anaesthetic. Islet transplants have been shown to reduce the risk of severe hypos.
Islet transplants usually also lead to improved awareness of hypoglycaemia, less variability in blood glucose levels, improved average blood glucose, improved quality of life and reduced fear of hypos. Long-term results are good and are improving all the time. For example, the majority of transplant patients can now expect to have a functioning transplant after six years and some people have had more than 10 years of clinical benefit.
- Xenotransplantation for the Treatment of Type 1 Diabetes
- Beta Cell Regeneration
- Clinical Trial on Islet Transplants
- Islet Cell Transplantation for Diabetes
- Pancreas Transplantation
- Kidney Transplants
Track 16: Metabolic Syndrome / Syndrome X:
Metabolic syndrome is a cluster of conditions — increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels — that occur together, increasing your risk of heart disease, stroke and diabetes. Metabolic syndrome is closely linked to overweight or obesity and inactivity.
It’s also linked to a condition called insulin resistance. Normally, your digestive system breaks down the foods you eat into sugar (glucose). Insulin is a hormone made by your pancreas that helps sugar enter your cells to be used as fuel.
In people with insulin resistance, cells don’t respond normally to insulin, and glucose can’t enter the cells as easily. As a result, glucose levels in your blood rise despite your body’s attempt to control the glucose by churning out more and more insulin.
There are new findings regarding the comorbidity associated with rheumatic diseases. Both psoriasis and psoriatic arthritis have been found to be associated with metabolic syndrome. Recent research indicates prolonged chronic stress can contribute to metabolic syndrome by disrupting the hormonal balance of the hypothalamic-pituitary-adrenal axis (HPA-axis).
- Abdominal (visceral Obesity)
- Atherogenic Dyslipidemia
- Post Meal Tiredness
- Acanthosis nigricans
- Oral glucose tolerance test (OGTT or GTT)
- Fatty liver disease and steatohepatitis
- Brain fog (Inability to focus properly)
Track 16: Clinical Diabetes and Diagnostic Approaches:
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels.
Diabetic kidney disease is recognized as the leading cause of excess mortality in the population with type 1 diabetes. The prevailing theory is that excess calories are processed via the mitochondria resulting in accumulation of superoxide radicals via the electron transfer chain. Novel Paradigms in Diabetic Complications, Diabetes, Pre-diabetes represents an elevation of plasma glucose above the normal range but below that of clinical diabetes. Prediabetes and Metabolic Syndrome, To better study both the pathogenesis and potential therapeutic agents, appropriate animal models of type 2 diabetes (T2D) mellitus are needed for Clinical trials on animal models, sodium glucose co-transport inhibitors act as a novel strategy for the treatment of diabetes mellitus.
Type 2 diabetes is by far the most common type of diabetes in adults (>90 percent) and is characterized by hyperglycemia and variable degrees of insulin deficiency and resistance in Clinical presentation and diagnosis of diabetes mellitus in adults.
- Novel paradigms in Diabetic Complications
- Clinical diagnosis and laboratory tests
- Diabetes, Prediabetes and Metabolic Syndrome
- Clinical trials on animal models
- Novel research and treatment strategies on diabetes
- Clinical presentation and diagnosis of diabetes mellitus in adults
- Clinical case reports and clinical endocrinology practices
Global Conference on Diabetes 2019 is anticipating around 300 participants around the globe and the two day conference will provoke Plenary sessions, Keynote speeches, Poster, and Oral presentations.
The Global Scientific Conferences invites all the participants across the globe to attend the Global Conference and expo on Diabetes, which will be held in March 11th-12th, 2019 Dubai UAE. which will provide an international platform for discussion of present and future challenging and emerging issues in Diabetes. Diabetes 2018 will also provide the excellent opportunity to meet Physicians, Researchers, Clinicians, Experts, Directors, Professors, Associate Professors, Dietitians, Certified diabetes educators, other health care professionals and who manage diabetes related complications
The main theme of Diabetes 2019 conference is : Innovative Ideas and Approaches for Striving the Future of Diabetes.
Global Conference on Diabetes 2019 is anticipating around 300 participants around the globe and the two day conference will provoke Plenary sessions, Keynote speeches, Poster, and Oral presentations.
Diabetes is a disease that affects your body’s ability to produce or use insulin. Insulin is a hormone. When your body turns the food you eat into energy (also called sugar or glucose), insulin is released to help transport this energy to the cells. Insulin acts as a “key.” Diabetes, often referred to by doctors as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body’s cells do not respond properly to insulin, or both.
Diabetes 2019 is an international platform for presenting research about diabetes management and therapeutics, exchanging ideas about it and thus, contributes to the dissemination of knowledge in management of the disease for the benefit of the society. Diabetes 2019 is where the future of management and novel therapeutics for the disease intersects.
The Annual conference aims to provide an opportunity to share knowledge, expertise along with unparalleled networking opportunities between a large number of medical and industrial professionals in this sphere. The meeting gathers renowned scientists, physicians, surgeons, young researchers, industrial delegates and talented student communities in the field of diabetic medicine under a single roof where networking and global partnering happens for the acceleration of future research.
The drugs market in field of internal Medicine especially in diabetes and Endocrinology in America is expected to reach USD 41 billion by 2020, growing at a CAGR of over 6percent.The drugs market in EMEA will exceed USD 16 billion by 2020, growing at a CAGR of over 6percent. The drugs market in APAC is expected to exceed USD 14 billion by 2020, growing at a CAGR of over 7percent. Key suppliers are Novo Nordisk, Sanofi, Merck, Eli Lilly, AstraZeneca, and AbbVie
Why to attend?
Diabetes 2019 highlights the theme “Innovative Ideas and Approaches for Striving the Future of Diabetes.” Which emphasis on the latest advancements in prevention and treatment cure of various metabolic diseases which may be due to diabetic and endocrine complications and provides robust discussions on methods and strategies related to diagnosis, prevention and management of metabolic disorders as well as explore new ideas and concepts for treatment of Endocrine Complications..
- Nurse educator
- Eye Doctors
- Physical trainer or Exercise physiologist
The GSC invites all the participants across the globe to attend the Global Conference and expo on Diabetes, which will be held in March 11th-12th, 2019 Dubai UAE. which will provide an international platform for discussion of present and future challenging and emerging issues in Diabetes. Diabetes 2018 will also provide the excellent opportunity to meet Physicians, Researchers, Clinicians, Experts, Directors, Professors, Associate Professors, Dietitians, Certified diabetes educators, other health care professionals and who manage diabetes related complications.
- Diabetes has increasingly become a lifestyle-related disease as it afflicts young and old. According to WHO Diabetes was estimated to affect 371 million people till the end of 2011in US. Whereas, new figures indicate that the number of people living with diabetes is expected to rise from 371 million in 2012 to 552 million by 2030. This indicates an urgent alarm for its management.
- “Regionally, we saw the largest increase in diagnosed diabetes prevalence in the South, followed by the West, Midwest, and Northeast,” with CDC’s Division of Diabetes Translation and lead author of the report. “These data also reinforce findings from previous studies, which indicate that the prevalence of diagnosed diabetes is highest in the southern and Appalachian states.”
As the number of patients grows across the globe, there has never been a stronger and more urgent need for therapeutic measures that arrest the growth of the disease and alleviate its secondary manifestations. In Type 1 diabetes total beta-cell loss occurs. In Type 2 diabetes, partial beta-cell loss occurs before diagnosis, and the progressive beta-cell loss during the life of the patient increases the severity of the disease. This addresses novel therapies for these deficiencies in clinical and preclinical evaluation.
Many International Conferences and Diabetic therapies meetings/ symposium and workshops have been organized on different topics related to the risk factors related to diabetes across the globe such as glucose tolerability conference, diabetes stem cell cure conference, anti-diabetic agents meetings, obesity conferences, weight loss conferences, Islet transplantation international conference, glucose variability conferences etc. Besides that many international events such as diabetes alternative medicines events, insulin pump therapy events, pancreatic dysfunction events, recombinant approaches for diabetes events etc. Targeted Therapy Events have been also taking place in order to find a weapon against fatal diseases like diabetic foot, insulin resistance, glucose tolerability, obesity and to discuss the role of diabetes in cardiovascular diseases, kidney diseases, risk of cancer and intolerability to cure the wound which will gives a better insight about the associated causes and disease portfolio.
Why in Dubai
The UAE has the second-highest diabetes rate in the world, with an estimated 20percent of residents and 25percent of nationals suffering from the disease. Nearly three-quarters of diabetes patients in the UAE do not have their diabetes under control, a challenge particularly pronounced among children and young adults. It is estimated that 40 to 50percent of diabetics in the UAE are unaware they even have the disease. Left unchecked, the spread of diabetes portends devastating social and fiscal consequences, including threats to economic progress and investment stability in the region.
The United Arab Emirates (UAE) has achieved an impressive level of economic development. In particular, its healthcare sector is among the best performing in the world. By many measures of health status (infant mortality, life expectancy, eradication of numerous infectious diseases), the UAE has reached levels comparable with other developed nations. In addition, the health infrastructure which includes facilities, equipment, and staff, are of high quality. This healthcare is offered freely or at low-cost to citizens and highly subsidised to residents and tourists. The fact that the UAE has made such great strides in achieving a high level of excellence in accommodating the healthcare needs of so many people is a testament to wise resource management policies. However, at least one health pandemic threatens to unravel the system’s stability: diabetes. The World Health Organization (WHO) and the International Diabetes Federation (IDF) call diabetes the 21st century’s leading healthcare challenge. Diabetes complications and mortality create social and economic challenges that affect individuals, families, businesses, and society as a whole. Six Middle East North Africa (MENA) region countries – Bahrain, Egypt, Kuwait, Oman, Saudi Arabia, and the United Arab Emirates (UAE) – are among the world’s 10 highest for prevalence of diabetes and impaired glucose tolerance. By 2020, 32percent of the adult UAE population (age 20-79) may have diabetes or pre-diabetes, while other data indicate that the adult UAE population (ages 18 and above) has already reached a diabetes or pre-diabetes rate of 44percent. If trends continue, the IDF projects that by 2030, the number of people with diabetes in the Middle East North Africa (MENA) region will almost double, reaching 59.7 million.
Major Diabetes Associations around the Globe
- Diabetes Indian Association
- Canadian Diabetes Association
- International Diabetes Federation
- Diabetes Australia
- Austrian Diabetes Association
- Diabetes UK
- Diabetes South Africa
- Spanish Diabetes Society (Spain)
- Swedish Diabetes Association
- Korean Diabetes Association
Major Diabetes Associations in Dubai
- Emirates diabetes society
- Global Health Partner Diabetes Centre Dubai
- Cleveland Clinic Dubai
- Joslin Diabetes Centre Dubai
- Al Jalila Foundation Research Centre in Dubai
- Diabetes Research Institute Dubai
- Diabetes Education in Tribal Schools (DETS)
- Imperial College London Diabetes Centre Dubai